Searched for
RA BIOSIMILAR
Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...- Hold Biocon, target price Rs 410: Anand RathiThe company has not provided any near term guidance due to ongoing Covid crises and would provide when more clarity emerges.
- Stocks in the news: Wipro, RIL, Hindalco, HDFC, Tata Steel, Welspun Corp and BioconIT major Wipro will announce its fourth-quarter and FY20 results today.
- Roche and Cipla tie up to market anti cancer drugsRoche said this partnership will also enable it to focus on bringing new, transformative medicines to patients in India.
- Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
- Ranbaxy enters into licensing pact with EPIRUS SwitzerlandRanbaxy Laboratories have entered into a licensing pact with EPIRUS Switzerland GmbH for treating rheumatoid arthiritis.
Load More